March 26, 2026
6:55 am
 — 
8:10 am
Non-CME/CE Bonus Presentation
Treating MDD with a Rapid-Acting Antidepressant That Modulates Both Glutamatergic and Monoaminergic Pathways
Sponsored by Axsome Therapeutics

Speaker: John J. Miller, MD

This branded symposium will highlight the current unmet needs in MDD and present a treatment option with rapid symptom improvement for adult patients with MDD.

March 26, 2026
12:05 pm
 — 
1:20 pm
Non-CME/CE Bonus Presentation
Tardive Dyskinesia Is Personal: Go Beyond the Data with a Real Patient Story
Sponsored by Neurocrine Biosciences

Speakers: Jeffrey Jon Hansen, MD & Patient Ambassador

March 27, 2026
7:00 am
 — 
8:00 am
Non-CME/CE Bonus Presentation
Real Voices, Real Challenges: Exploring the Dimensions of TD Impact and the Importance of Regular Assessment
Sponsored by Teva Pharmaceuticals

Speaker: Richard Jackson, MD

March 27, 2026
9:20 am
 — 
10:20 am
Non-CME/CE Bonus Presentation
Learn About a Different Treatment Option for Adults with Schizophrenia: Where Does it Fit in Your Practice?
Sponsored by Bristol Myers Squibb

Speaker: Leslie Citrome, MD

Don’t miss this opportunity to learn about a different treatment option for adults with schizophrenia. Discover its clinical profile as well as practical considerations for prescribing it. The program also highlights unmet needs in the treatment of schizophrenia.

March 27, 2026
12:40 pm
 — 
1:40 pm
Non-CME/CE Bonus Presentation
Challenges in Achieving Symptom Control in Major Depressive Disorder: Considering Adjunctive Treatment Options
Sponsored by Johnson & Johnson

Speaker: Mark Zimmerman, MD

This program focuses on the implications of unresolved symptoms in patients with major depressive disorder treated with antidepressant monotherapy. We will review common barriers to full remission, evaluate the rationale for adjunctive atypical antipsychotic therapy, and discuss clinical trial evidence that can guide psychiatric treatment decisions.

March 28, 2026
11:45 am
 — 
12:45 pm
Non-CME/CE Bonus Presentation
Identifying Appropriate Candidates for LAIs and Understanding the Pharmacokinetic Features
Sponsored by Teva Pharmaceuticals

Speaker: Leslie Citrome, MD

Identifying appropriate patients for LAIs, and pharmacokinetic features of LAIs.

March 27, 2026
5:30 pm
 — 
6:45 pm
Independent CME Symposium
The Patient Voice in MDD: Why and When to Augment Therapy
Supported by an independent educational grant from Johnson & Johnson
Additional 1.0 CME credit(s)

Moderator: Leslie Citrome, MD, MPH

Speakers: Paul P. Doghramji, MD; Joseph F. Goldberg, MD

Step beyond traditional learning and into the real world of patient-centered psychiatry. This innovative program puts YOU at the intersection of clinical expertise and authentic patient experiences, equipping you with insights and strategies that will reshape the way you care for your patients with major depressive disorder.

Based on immersive, small-group Patient Journey Stations, dive deep into 3 powerful case studies mirroring real-world practice. You will:

  • Hear the real voices of patients
  • Engage directly with Faculty and colleagues for the exchange of ideas
  • Ask questions in an informal setting
  • Experience interactive, live panel discussions that bridge patient perspectives with clinical excellence

Take advantage of this opportunity to enhance your clinical practice!

NOTE: Bonus presentations are independently organized and not an official part of Psychiatry Update 2026. CME/CE credit is not provided for these sessions.